References
- Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521–2532 (2008).
- Agnandji ST, Lell B, Soulanoudjingar SS et al.; RTS,S Clinical Trials Partnership. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365(20), 1863–1875 (2011).
- Smith T, Killeen GF, Maire N et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: overview. Am. J. Trop. Med. Hyg. 75(2 Suppl.), 1–10 (2006).
- Smith T, Ross A, Maire N et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med. 9(1), e1001157 (2012).
- Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am. J. Trop. Med. Hyg. 75(2 Suppl.), 111–118 (2006).
- Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 3(9), e3193 (2008).
- Brooks A, Briët OJ, Hardy D, Steketee R, Smith TA. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission. PLoS ONE 7(3), e32587 (2012).
- Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M. Predicting the cost–effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am. J. Trop. Med. Hyg. 75(2 Suppl.), 131–143 (2006).
- Tediosi F, Maire N, Penny M, Studer A, Smith TA. Simulation of the cost–effectiveness of malaria vaccines. Malar. J. 8, 127 (2009).
- Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost–effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 14(8), 1028–1038 (2011).
- Struchiner CJ, Halloran ME, Spielman A. Modeling malaria vaccines. I: new uses for old ideas. Math. Biosci. 94(1), 87–113 (1989).
- Griffin JT, Hollingsworth TD, Okell LC et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 7(8), e1000324 (2010).
- Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 31(9), 492–500 (2009).
- Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. 2, CD000363 (2004).
- Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar. J. 11, 11 (2012).
- malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 8(1), e1000398 (2011).
- malERA Consultative Group on Modeling. A research agenda for malaria eradication: modeling. PLoS Med. 8, e1000403 (2011).
- Mantel C, Wang SA. The privilege and responsibility of having choices: decision-making for new vaccines in developing countries. Health Policy Plan. 27(Suppl. 2), ii1–ii4 (2012).
- WHO. World Malaria Report 2010. WHO, Geneva, Switzerland (2011).
- Leach-Kemon K, Chou DP, Schneider MT et al. The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff. (Millwood) 31(1), 228–235 (2012).